Evonile Pharma Limited
Key Approvals and Financial Figures
The Board of Directors approved the issuance of partly paid-up equity shares by way of a rights issue to eligible equity shareholders for an aggregate amount of up to ₹9,000 million (Rupees Nine Thousand Million only). This approval follows a previous board meeting dated October 08, 2026.
Committee Authorization
The Board authorized a 'Rights Issue Committee' to decide on the terms and conditions of the Rights Issue. This includes setting the record date, Issue Price, Right entitlement ratio, and other related matters in accordance with applicable laws, including the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
Additional Approvals
In relation to the Rights Issue, the Board also approved the payment schedule and the utilization of the issue proceeds. The Board approved the Letter of Offer, which is to be filed with BSE Limited and the Securities and Exchange Board of India (SEBI). The approved Letter of Offer will be dispatched to the eligible equity shareholders of the Company.
Meeting Details
The board meeting concluded at 05:20 P.M. IST on November 04, 2026.
Additional Information
The disclosure states that this information will also be available on the company's new website at www.evonilepharma.com.
Company and Contact Information
The disclosure is signed by Ms. Chandni Maru, Company Secretary and Compliance Officer (A60291). The company's registered office is Inspire BKC, 7th Floor, Bandra - Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. Its Corporate Identification Number (CIN) is L24200MH1947PLC006104. Contact details include Tel: +9122 50243000, Email: investor.relations@evonilepharma.com.